Human immunodeficiency virus epitopes (HIV epitopes)

Human immunodeficiency virus (HIV) epitopes are specific molecular structures within viral proteins—such as the envelope glycoproteins (gp120, gp41), Gag, Pol, and Nef—that are recognized by the host's immune system (Los Alamos HIV Database, 2023). These epitopes serve as the primary targets for the development of prophylactic and therapeutic vaccines, as well as monoclonal antibody therapies (NIAID, 2024). Because HIV-1 exhibits extreme genetic diversity and a high mutation rate, targeting multiple HIV epitopes is a strategic approach to ensure broader coverage across different viral clades and to prevent the emergence of escape mutants (PubMed: 31534225). Therapeutic interventions often utilize polyepitope constructs or combinations of broadly neutralizing antibodies (bNAbs) like VRC01 or 10-1074 to target conserved regions of the viral spike (Nature, 2018). The ultimate goal of targeting these epitopes is to elicit a robust immune response, characterized by high titers of neutralizing antibodies and potent T-cell activity, to either prevent initial infection or achieve a functional cure in people living with HIV (NIH, 2023).

Other names

HIV-1 epitopesHIV antigenic determinantsHIV polyepitopesHIV-1 antigens

Induction of humoral and cellular immune responses, including the production of neutralizing antibodies and activation of CD8+ cytotoxic T-cells to recognize and eliminate HIV-infected cells.